Company / Interest Expense
Neurocrine Biosciences Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$4.6M
FY2023
5-year range
$4.6M / $25.8M
FY2019-FY2023
Trend
-35.2%
vs FY2022
Sector context
#34 of 42
Health Care
What the data says
Neurocrine Biosciences's interest expense of $5M is lower than 81% of companies in the Health Care sector (FY2023). Interest Expense has declined for 3 consecutive years, from $33M in FY2020 to $5M in FY2023.
Based on SEC 10-K filings.
$5M in FY2023 with a 5-year CAGR of -31.5%.
Improved from $26M to $5M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -48.0%
- 5-Year CAGR
- -31.5%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 42This company $4.6M Sector average $305.3M
▼
-98.5% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's interest expense has declined for 3 consecutive years.
- 5-year CAGR of -31.5%, indicating a declining trend.
- In FY2023, interest expense decreased 35.2% year-over-year.
- Ranks #34 out of 42 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $4.6M | -35.2% |
| FY2022 | $7.1M | -72.5% |
| FY2021 | $25.8M | -21.3% |
| FY2020 | $32.8M | +2.5% |
| FY2019 | $32.0M | +4.9% |
| FY2018 | $30.5M | +56.2% |
| FY2017 | $19.5M | - |
| FY2016 | $0 | - |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026